Project Grant K23HL173650
Award Date
8/1/25
Completion Date
5/31/30
Dollars Obligated
$198K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $189,000.00 to the University of Utah to conduct a 5-year research program with the goal of developing the Principal Investigator into an independent, patient-oriented clinical researcher focusing on the pathophysiology of cardiogenic shock (CS) and its overlap with the cardiorenal syndrome. The key objectives of the research are to: 1) evaluate the...
This federal Project Grant award of $107,298 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine the mechanisms underlying the specific regulation of cardiac cardiolipin, a phospholipid crucial for mitochondrial energy production in the heart. The research aims to: 1) evaluate the significance and preference of linoleic acid-cardiolipin in cardiac energy production; 2) characterize the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $554,737 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The University of Texas Southwestern Medical Center, with a project period from Sep 1, 2024 to Jun 30, 2029. The objective of this grant is to leverage multi-omic technologies to identify novel pre-transplant biomarkers associated with clinically significant rejection within the first year following heart transplantation. The research will involve proteomic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,057,973 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Johns Hopkins University to conduct research on modeling fetal lung development in congenital diaphragmatic hernia (CDH). The research aims to investigate the role of the YAP/TAZ mechanosensing pathway in CDH lung hypoplasia using mouse models, human lung organoids, and large animal fetal models. The research teams led by Shaun Kunisaki, Jason...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $137,219 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois in Chicago. The goal of this 5-year grant is to develop the skills of Dr. Santosh L. Saraf, a mid-career hematologist and physician-scientist, to mentor the next generation of junior investigators focused on sickle cell disease (SCD)-related research. The research aims to investigate genetic factors and the role of complement...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $380,383 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The 3-year grant, awarded on Apr 21, 2025, aims to investigate the role of aldehyde-detoxifying enzymes in protecting hematopoietic stem cells (HSCs) from endogenous DNA damage, with the goal of developing novel therapeutic strategies to prevent bone marrow failure and malignancies in Fanconi anemia patients....
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
The University of Maryland, Baltimore received a $678,445 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to study a novel regulator of cardiomyocyte function and homeostasis. The research aims to determine the mechanisms by which the C5ORF51 (C5X) protein modulates transcription in cardiomyocytes and investigate its role in adult cardiomyocyte proliferation and maturation. This innovative research has the potential to uncover...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...